MetLife is one of the largest life insurers in the US by assets and provides a variety of life insurance and annuity products... Show more
MetLife, Inc. (NYSE: MET) has sustained a steady climb through mid-2026, with the stock advancing from the mid-$70s in April to $94.00 by mid-July. The nearly 10% move over the past 30 days reflects a confluence of strong quarterly results, constructive analyst commentary, robust institutional demand, and ongoing capital-return initiatives. Trading at approximately 18 times trailing earnings with a beta of 0.78, MET has attracted attention from value-oriented and income-focused investors alike. The stock's 50-day simple moving average sits near $85.80, well above the 200-day moving average of roughly $79.07, confirming a bullish intermediate-term trend.
Founded in 1868 and headquartered in New York City, MetLife is one of the world's largest financial services companies, providing life insurance, annuities, employee benefits, and asset management solutions across more than 40 markets globally. The company maintains leading positions in the United States, Asia, Latin America, Europe, and the Middle East. Its diversified business mix spans group benefits, retirement and income solutions, and international life and health operations, generating multiple revenue streams that help buffer regional economic cycles. Through its investment management arm — recently strengthened by the PineBridge acquisition — MetLife manages a substantial general account portfolio alongside third-party institutional assets. With a market capitalization near $60 billion and a track record of consistent dividend growth, the company occupies a blue-chip position within the insurance and diversified financials sector.
Several developments during the last month have shaped investor perception of MetLife. On July 7, the board declared a Q3 2026 common stock dividend of $0.5925 per share, underscoring management's commitment to shareholder returns. The same week brought a flurry of analyst activity: Morgan Stanley raised its price target from $93 to $103 (Overweight), Jefferies lifted its target from $97 to $103 (Buy), Wells Fargo moved from $95 to $101 (Overweight), and Mizuho increased its target from $95 to $102 (Outperform). Keefe, Bruyette & Woods also set a Street-high target of $105.
On the operational side, MetLife filed preliminary Q2 variable investment income estimates of approximately $220 million to $270 million pretax — below the annualized run rate but consistent with typical quarterly variability in private equity and real estate returns. The company scheduled its full Q2 2026 earnings release for August 5, after market close, with a conference call the following morning. Meanwhile, institutional filings continued to show broad ownership, with 13F disclosures revealing new or expanded positions from SEB Asset Management AB, International Assets Investment Management, and Valley Wealth Managers, partially offset by modest trimming at Jennison Associates.
For traders seeking a data-driven edge in analyzing stocks like MetLife, Tickeron's Trending AI Robots page provides a curated window into the platform's most relevant AI-powered trading tools. Tickeron offers hundreds of AI trading bots that actively trade thousands of tickers across diverse strategies, timeframes, and performance profiles — yet only the top-performing and most contextually relevant bots appear in this focused section. These AI robots range from short-term momentum strategies to longer-term value and swing-trading models, each accompanied by transparent performance metrics and trade histories. The Trending AI Robots section helps investors quickly identify which automated strategies are currently generating the strongest signals across the market.
MetLife's second-quarter earnings report, due August 5, represents the most immediate catalyst for the stock. Consensus estimates point to EPS of approximately $2.35, and investors will closely scrutinize adjusted premiums, fees and other revenues (which grew 10% year-over-year in Q1), group benefits sales momentum, and Asia-Pacific performance — a region that delivered 31% earnings growth last quarter. The pace of share buybacks (with roughly $1.1 billion remaining on the current authorization) and holding-company liquidity will also be in focus. On the macroeconomic front, interest-rate expectations, credit spreads, and currency fluctuations — particularly the yen and emerging-market exposures — remain key variables affecting MetLife's investment portfolio and international earnings translation. The PineBridge integration represents both a growth opportunity and an expense-management challenge, with management targeting a direct expense ratio of 12.1% for the full year. Regulatory capital ratios, currently well above internal targets, provide a cushion against market volatility.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
MET saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on July 23, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 50 instances where the indicator turned negative. In of the 50 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .
The 10-day RSI Indicator for MET moved out of overbought territory on July 20, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 45 similar instances where the indicator moved out of overbought territory. In of the 45 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 70 cases where MET's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MET declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
MET broke above its upper Bollinger Band on July 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Momentum Indicator moved above the 0 level on July 02, 2026. You may want to consider a long position or call options on MET as a result. In of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MET advanced for three days, in of 342 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 272 cases where MET Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. MET’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 62, placing this stock better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.179) is normal, around the industry mean (1.485). P/E Ratio (17.899) is within average values for comparable stocks, (13.759). Projected Growth (PEG Ratio) (0.489) is also within normal values, averaging (1.435). Dividend Yield (0.025) settles around the average of (0.045) among similar stocks. P/S Ratio (0.811) is also within normal values, averaging (1.403).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of insurance and financial services and also function as bank holding company
Industry LifeHealthInsurance